OPEN ACCESS Freely available online

Mycobacterial Diseases

ISSN: 2161-1068

Short Communication

Tuberculosis Vaccines: A Beacon of Hope in Global Health

Rongbin Quin*

Departments of Laboratory Medicine and Microbiology, Tumour and Cell Biology, Karolinska Institute, Stockholm, Sweden

DESCRIPTION

Tuberculosis (TB) has been a persistent threat to human health for centuries, affecting millions of people worldwide each year. While significant progress has been made in TB diagnosis and treatment, the development of an effective vaccine remains a important goal in the fight against this infectious disease. In recent years, research efforts have intensified, aiming to produce vaccines capable of preventing TB infection and reducing its global burden. TB is caused by the bacterium *Mycobacterium tuberculosis*, which primarily affects the lungs but can also target other organs in the body. It spreads through the air when an infected person coughs or sneezes, making it highly contagious. The World Health Organization (WHO) estimates that over 10 million people develop active TB annually, with around 1.4 million deaths attributed to the disease each year.

The Bacillus Calmette-Guérin (BCG) vaccine, developed in the early 20th century, is currently the only licensed TB vaccine available worldwide. While BCG vaccination provides protection against severe forms of TB in children, its efficacy in preventing adult pulmonary TB, the most common form of the disease, is variable and often limited. As a result, there is an urgent need for new and improved TB vaccines to address the limitations of BCG and provide broader protection against TB infection [1]. Several promising TB vaccine candidates are currently in various stages of clinical development, offering hope for more effective TB prevention strategies. These vaccine candidates target different aspects of the TB infection process, including boosting the immune response to *M. tuberculosis* and preventing the establishment of latent TB infection, which can later progress to active TB disease [2].

One of the most advanced TB vaccine candidates is M72/AS01E, developed by GlaxoSmithKline (GSK) in collaboration with the non-profit organization Aeras. M72/AS01E is a protein subunit vaccine that targets proteins expressed by *M. tuberculosis* during infection. Clinical trials have shown that M72/AS01E can significantly reduce the risk of TB disease in adults with latent TB infection, representing a significant step forward in TB vaccine development [3]. Another promising TB vaccine candidate is VPM1002, a recombinant BCG vaccine engineered to enhance its immunogenicity and protective efficacy. VPM1002 has shown promising results in preclinical and early clinical studies, demonstrating improved protection against TB infection compared to conventional BCG vaccination. VPM1002 is currently undergoing further evaluation in clinical trials to assess its safety and efficacy in different populations.

Other TB vaccine candidates in development include adenovirus-based vaccines, viral vector vaccines, and live attenuated vaccines, each targeting different aspects of the TB infection process. These vaccines aim to stimulate both cellular and humoral immune responses, providing comprehensive protection against TB infection and disease progression [4]. Despite the progress in TB vaccine research, several challenges remain in the development and implementation of effective TB vaccines. One major challenge is the complexity of the TB infection process, which involves intricate interactions between the bacterium and the host immune system. Developing vaccines that can overcome the immune evasion strategies employed by *M. tuberculosis* and induce long-lasting protective immunity remains a significant hurdle.

Furthermore, the high cost and lengthy timelines associated with TB vaccine development pose challenges for research funding and resource allocation. TB vaccine development requires substantial investment in preclinical research, clinical trials, and regulatory approval processes, which can hinder progress in bringing new vaccines to market [5]. Additionally, the global distribution and administration of TB vaccines present logistical challenges, particularly in resource-limited settings where TB burden is highest. Ensuring equitable access to TB vaccines for vulnerable populations, including infants, children, and people living with HIV, is essential in achieving global TB control goals. Despite these challenges, the ongoing efforts to develop new TB vaccines offer hope for a future where TB can be effectively prevented and controlled. Collaborative partnerships between governments, non-profit organizations, academic institutions,

Correspondence to: Rongbin Quin, Departments of Laboratory Medicine and Microbiology, Tumour and Cell Biology, Karolinska Institute, Stockholm, Sweden, E-mail: r.baarlen@gierc.nl

Received: 27-Feb-2024, Manuscript No. MDTL-24-31086; **Editor assigned:** 29-Feb-2024, Pre QC No. MDTL-24-31086 (PQ); **Reviewed:** 14-Mar-2024, QC No. MDTL-24-31086; **Revised:** 21-Mar-2024, Manuscript No. MDTL-24-31086 (R); **Published:** 28-Mar-2024, DOI: 10.35248/2161-1068.24.14.443

Citation: Quin R (2024) Tuberculosis Vaccines: A Beacon of Hope in Global Health. Mycobact Dis. 14:443.

and pharmaceutical companies are essential in advancing TB vaccine research and accelerating progress towards ending the TB epidemic.

CONCLUSION

TB vaccines represent a critical tool in the fight against tuberculosis, offering the potential to prevent TB infection and reduce its global burden. While challenges remain in TB vaccine development and implementation, ongoing research efforts hold promise for the development of more effective TB vaccines in the future. By investing in TB vaccine research and ensuring equitable access to vaccines, we can move closer to achieving the goal of a world free from TB.

REFERENCES

1. Gulati A, Anudeep TC, Jeyaraman M, Sushmitha ES, Arora A, Jain R, et al. BCG vaccination: A beacon of hope with a word of caution-an overview on the current consensus in COVID-19. IJMCI. 020;7(5):4810-4821.
2. Stern AM, Markel H. The history of vaccines and immunization: Familiar patterns, new challenges. Health Aff. 2005;24(3):611-621.
3. Frist WH. Medicine as a currency for peace through global health diplomacy. Yale L and Pol'y Rev. 2007;26(S):209.
4. Chen CH, Chen YM, Lee CW, Chang YJ, Cheng CY, Hung JK. Early diagnosis of spinal tuberculosis. J Formos Med Assoc. 2016;115(10):825-836.
5. Hossain MJ, Rahman SM, Emran TB, Mitra S, Islam MR, Dhama K. Recommendation and roadmap of mass vaccination against coronavirus disease 2019 pandemic in Bangladesh as a lower-middle-income country. Arch Razi Inst. 2021;76(6):1823-1830.